A securities class action lawsuit has been filed against Corcept Therapeutics Incorporated, with plaintiffs claiming the company made materially false and misleading statements regarding clinical trial data for its investigational drug relacorilant. The complaint alleges that Corcept presented overstated projections concerning the likelihood of FDA approval for the candidate treatment's New Drug Application, while simultaneously withholding material information about known risks that could result in regulatory rejection.
According to the lawsuit, investors were not adequately informed of risks associated with the NDA filing, which the complaint suggests the company was aware could prevent FDA approval. The allegations suggest a pattern of disclosure failures that may have affected investor decision-making regarding their positions in the company.
The case seeks to represent investors who purchased Corcept securities during the relevant period and sustained losses as a result of the alleged misstatements and omissions. Corcept Therapeutics has not yet responded publicly to the legal action. The outcome of this litigation could have significant implications for the company's regulatory standing and market valuation.